Designation: Senior Research scientist
Department: Biochemistry & Molecular biology
University: Port-Said University
Dr. Hassan Shora is a senior researcher at Port-Said university, member of supervising committee of PhD & MSc theses in molecular medicine cooperating with staff of department of biochemistry & molecular biology at faculty of science. He also is the Head of medicine & Director of diabetes center at Ismailia General Hospital and works as a senior lecturer, Egyptian Board of physicians to train medical residents in Ismailia, Egypt. Dr. Shora is awarded Physician Recognition Award of The American Medical Association in 2003-2006 and 2007-2010. He published his first paper in 1984 while he was a second year undergraduate student and published several original research papers thereafter in international journals in role of adiponectin and glycemic control in delaying subclinical atherosclerotic changes in type 1 diabetics, markers of subclinical atherosclerosis in type 1 diabetics, visceral fat and liver size as determinants of subclinical arthrosclerosis in type 1 diabetic adolescents, inflammatory biomarkers of cardio metabolic risk in obese type 2 diabetics, iron binding stores in correlation with cardio metabolic risk in obese type 2 diabetics, hormonal metabolic and radiological markers of subclinicl atherosclerosis in type 1 diabetics and NT ProPNB as a marker of microvascular complications in type 2 diabetes. Dr. Shora is a member of Asian Council of Science Editors and Editor of Clinical Endocrinology and Diabetes, Reports in Endocrine Disorders, SM journal of general medicine, Current Trends in General Practice and is working as editorial board member and peer reviewer for thirty journals worldwide including journals of Diabetes& Diabetes Care.
Dr. Shora researches interest in molecular diabetic medicine for novel biomarkers to detect early complications of diabetes. Interests: Adiponectin, adipose tissue, obesity, atherosclerosis, diabetic microvascular complications, cardiometabolic risk, novel anti-inflammatory therapies MoAb, for CVD prevention, systems and precision medicine for diabetes management.
Boffin Access Limited is committed to maintaining the integrity of the scholarly record to researchers. Therefore violation of professional ethical codes may lead to retract articles. Article(s) may be retracted if it is found to have serious flaws, reported misconduct research, constitute copyright infringement and plagiarism.
To help avoid the incorrect or misleading publications, please drop your message to
Enter your e-mail address to stay informed about published articles, issue releases and latest updates on journal activities.
We openly welcome feedback and constructive criticism. Your compliments, concerns and suggestions regarding our services will prove enormously helpful in making them even better.
Do you have an idea or suggestion that can influence the Open Access community? Send an email to: email@example.com
Copyright © 2020 Boffin Access Limited.